CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2016 European Hematology Association Congress
Oncology Conference Multimedia
View more videos >>
Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma
Dr. Raoul Tibes Discusses FLT3 Inhibitors in AML
Dr. Max Topp on the TOWER study and Blinatumomab in ALL
Oncology Conference Articles
Inotuzumab Ozogamicin Improves Outcomes in Relapsed/Refractory ALL
Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.
Long-Term COMFORT-I Data Confirm Ruxolitinib Survival Benefit
Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.
Antibodies From Cured AML Patients Kill Leukemia Cells
Patients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.
Daratumumab Triplet Reduces Risk of Progression by 63% in Myeloma
Combining the CD38-targeted antibody daratumumab with lenalidomide and dexamethasone reduced the risk of disease progression by 63% versus lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III POLLUX (MMY3003) trial.
Targeted Therapies Could Revolutionize AML Treatment
A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.
Vadastuximab Talirine, HMA Combo Induces Impressive Remissions in AML
Frontline treatment with the CD33-directed antibody-drug conjugate vadastuximab talirine plus a hypomethylating agent induced deep and durable remissions for older patients with acute myeloid leukemia.
Stopping TKIs Proven Safe in Chronic Phase CML
Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.
Blinatumomab Nearly Doubles Survival in Acute Lymphoblastic Leukemia
The median overall survival with the anti-CD19 immunotherapy blinatumomab was 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study.
Ibrutinib Highly Effective for Del17p CLL in Combined Analysis
Ibrutinib continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.
FDA Approval in HCC, Breakthrough Designation in MCL, and More
Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment
Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC
SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer
Novel Strategies Emerging in Uterine Sarcomas
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.